IP Library Granted Patent US 11,740,219
Granted Patent B2
US 11,740,219 · App. 17/730,853 · Granted Aug 29, 2023

Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient

Inventors: Takeshi Wakasugi (Osaka, JP); Aya Sano (Osaka, JP)
Assignee: MITSUBISHI TANABE PHARMA CORPORATION
G01N33/15A61K31/415A61K31/4152G01N30/06G01N2030/027G01N2030/042G01N2030/067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,740,219
App. No.
17/730,853
Granted
Aug 29, 2023
Kind
B2
Abstract

A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 μg/mL to 10 μg/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value. The first acidic water is hydrochloric acid, and/or an aqueous acetic acid solution, the first water-soluble organic solvent is acetonitrile and/or methanol, the second acidic water is hydrochloric acid, and/or an aqueous acetic acid solution, and the second water-soluble organic solvent is acetonitrile and/or methanol.

Claims (12)

1. A method of analyzing a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, comprising:

obtaining a first measured value by measuring a phenylhydrazine content in a phenylhydrazine standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration in a range of 0.01 μg/mL to 10 μg/mL;

obtaining a second measured value by measuring a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent; and

detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and the second measured value,

wherein the first acidic water includes hydrochloric acid and has an acid concentration in a range of 0.1 mol/L to 1 mol/L, the first water-soluble organic solvent is acetonitrile and has a volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution in a range of 6:4 to 7:3, the second acidic water includes hydrochloric acid and has an acid concentration in a range of 0.1 mol/L to 1 mol/L, and the second water-soluble organic solvent is acetonitrile and has a volume ratio of the second acidic water and the second water-soluble organic solvent in the 3-methyl-1-phenyl-2-pyrazoline-5-one sample solution in a range of 6:4 to 7:3.

2. The method according to claim 1 , further comprising:

preparing the phenylhydrazine standard solution; and

preparing the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution.

3. The method according to claim 1 , wherein the first measured value is obtained by measuring the phenylhydrazine content in the phenylhydrazine standard solution using high performance liquid chromatography, and the second measured value is obtained by measuring the phenylhydrazine content in the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution using high performance liquid chromatography.

4. The method according to claim 1 , wherein the acid concentration of the first acidic water is 0.1 mol/L, and the acid concentration of the second acidic water is 0.1 mol/L.

5. The method according to claim 1 , wherein the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution is 7:3, and the volume ratio of the second acidic water and the second water-soluble organic solvent in the 3-methyl-1-phenyl-2-pyrazoline-5-one sample solution is 7:3.

6. The method according to claim 1 , wherein the acid concentration of the first acidic water is 1 mol/L, and the acid concentration of the second acidic water is 1 mol/L.

Assignments (3)
CHANGE OF NAME Recorded Apr 22, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: TANABE PHARMA CORPORATION
Reel/Frame 075454/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2026
From: TANABE PHARMA CORPORATION
To: SHIONOGI INC.
Reel/Frame 074428/0218 →
CHANGE OF NAME Recorded Mar 5, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: TANABE PHARMA CORPORATION
Reel/Frame 073977/0840 →
Continuity (3)
Division 17536947 · Nov 29, 2021
Continuation 16976287
Related Publication 20220252569A1 · Aug 11, 2022
Cited By (1)
US 12,320,793